Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0153470 (Spleen)
 4,015 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serum thymic factor (FTS) reduced mortality of mice after total-body irradiation with 7.56 Gy X rays. The radioprotective effect was achieved by daily repeated subcutaneous injections of 3-100 micrograms FTS, while doses higher than 300 micrograms/day/mouse were neither radioprotective nor toxic. Similarly, degeneration of the spleen was moderated by 3-100 micrograms FTS but not by 500 micrograms FTS in sublethally (3.78 Gy) irradiated mice. Histological examination showed that hematopoiesis was enhanced in the spleen by daily injections of 10 micrograms FTS. Spleen cells from the FTS-treated mice incorporated more [3H]thymidine in culture with or without concanavalin A. The treatment with FTS increased the production of colony-stimulating factor in the spleen as well as in peritoneal macrophage-like cells, and caused a significant increase in the number of granulocyte-macrophage colony-forming cells both in the spleen and in the femoral bone marrow. Furthermore, FTS prevented a decrease in circulating neutrophils in the sublethally irradiated mice. Prominent overshoot recovery of myelopoiesis, which occurred occasionally in sublethally irradiated mice, did not occur in the FTS-treated mice. The decrease in blood erythrocytes was also significantly reduced. These observations imply that this thymic hormone has potential as a radioprotector.
 ...
PMID:Radioprotective effects of serum thymic factor in mice. 154 23

Anti-islet immune reactions were studied in vitro in genetically diabetic homozygote C57BL/KsJ db/db mice, using murine islet cells as a target. Spleen lymphocytes inhibited insulin secretion by the islet cells. This inhibition was abolished when T-cells were eliminated by treatment with anti-Thy 1.2 monoclonal antibody in the presence of complement. Anti-islet complement-dependent antibody (CDA) and antibody-dependent cell cytotoxicity (ADCC) were also found in the sera of these mice. This anti-islet immunity was detectable as early as the tenth day of life and lasted throughout the entire life span of the animals. A significant lymphopenia was detected in thymus and spleen cell populations. None of these anomalies was found in control heterozygote mice. Thymic function was explored in the same mice by evaluating their serum thymic factor (FTS) levels using a rosette assay. The age-dependent decline of FTS levels was significantly accelerated in diabetic mice as compared with heterozygous littermates. Furthermore, FTS inhibitory immunoglobulins were detected in db/db mouse sera, which inactivated in vitro the biologic potency of synthetic FTS. Histologically, the thymus displayed an accelerated involution. It was shown by indirect immunofluorescence using anti-FTS monoclonal antibodies that the number of FTS+ cells was reduced in db/db mouse thymuses. Histologic study of the islets of Langerhans showed early signs of beta-cell hyperactivity and hypertrophy, followed by beta-cell rarefaction and profound dislocation of islet architecture. Insulitis was not detected.
 ...
PMID:Anti-islet immunity and thymic dysfunction in the mutant diabetic C57BL/KsJ db/db mouse. 635 3

A synthetic serum thymic factor (FTS) augmented the lipopolysaccharide (LPS)-induced polyclonal B-cell responses in vitro of CBA/N mice and their F1 hybrids having an X-linked B-cell defect. For this augmentation, FTS should be injected in vivo. Splenic B cells derived from FTS-treated mice with the CBA/N defect were receptive to T-cell help from normal or immunodeficient mouse T cells. Thus, the inability of B cells from mice with the CBA/N defect to accept T -cell help may not be caused by an intrinsic T-cell defect, but by a functional B-cell defect that can be corrected by treatment with FTS in vivo. Spleen cells from ATXBM CBA/N mice treated with FTS 3 weeks after cell transfer did not increase the B-cell response. B cells from FTS-treated male F1 mice with the CBA/N defect still have characteristics of neonatal mouse B cells as revealed by inhibition with antimouse Ig and anti-Ia sera. These findings suggest that FTS may act on generation of a B-cell acceptor for T -cell help, rather than on the maturation of a B-cell subset.
 ...
PMID:Activation of polyclonal antibody responses by a synthetic serum thymic factor (FTS) in CBA/N mice. 703 18